Skip to main content
Journal cover image

Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

Publication ,  Journal Article
Hudson, MP; Armstrong, PW; Ruzyllo, W; Brum, J; Cusmano, L; Krzeski, P; Lyon, R; Quinones, M; Theroux, P; Sydlowski, D; Kim, HE; Garcia, MJ ...
Published in: J Am Coll Cardiol
July 4, 2006

OBJECTIVES: We sought to determine whether matrix metalloproteinase (MMP) inhibitor, PG-116800, reduced left ventricular (LV) remodeling after myocardial infarction (MI). BACKGROUND: PG-116800 is an oral MMP inhibitor with significant antiremodeling effects in animal models of MI and ischemic heart failure. METHODS: In an international, randomized, double-blind, placebo-controlled study, 253 patients with first ST-segment elevation MI and ejection fraction between 15% and 40% were enrolled 48+/- 24 h after MI and treated with placebo or PG-116800 for 90 days. Major efficacy end points were changes in LV volumes as determined by serial echocardiography, and clinical and safety outcomes were also collected. RESULTS: In total, 203 patients (80%) completed 90 days of treatment and had evaluable baseline and 90-day echocardiograms. The proportion of patients with anterior MI (78% vs. 81%) and primary percutaneous coronary intervention (90% vs. 91%) along with baseline LV ejection fraction (35.5% vs. 36.8%) did not differ between PG-116800-treated and placebo-treated patients. There was no difference in the change in LV end-diastolic volume index from days 0 to 90 with PG-116800 versus placebo (5.09 +/- 1.45 ml/m(2) vs. 5.48 +/- 1.41 ml/m2, p = 0.42). Changes in LV diastolic volume, LV systolic volume, LV ejection fraction, sphericity index, plus rates of death or reinfarction were not significantly improved with PG-116800. PG-116800 was well tolerated; however, there was increased incidence of arthralgia and joint stiffness without significant increase in overall musculoskeletal adverse events (21% vs. 15%, p = 0.33). CONCLUSIONS: Matrix metalloproteinase inhibition with PG-116800 failed to reduce LV remodeling or improve clinical outcomes after MI.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

July 4, 2006

Volume

48

Issue

1

Start / End Page

15 / 20

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Function, Left
  • Treatment Outcome
  • Myocardial Infarction
  • Middle Aged
  • Matrix Metalloproteinase Inhibitors
  • Male
  • Hydroxamic Acids
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hudson, M. P., Armstrong, P. W., Ruzyllo, W., Brum, J., Cusmano, L., Krzeski, P., … Weaver, W. D. (2006). Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol, 48(1), 15–20. https://doi.org/10.1016/j.jacc.2006.02.055
Hudson, Michael P., Paul W. Armstrong, Witold Ruzyllo, Jose Brum, Lisa Cusmano, Piotr Krzeski, Robert Lyon, et al. “Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.J Am Coll Cardiol 48, no. 1 (July 4, 2006): 15–20. https://doi.org/10.1016/j.jacc.2006.02.055.
Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006 Jul 4;48(1):15–20.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

July 4, 2006

Volume

48

Issue

1

Start / End Page

15 / 20

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Function, Left
  • Treatment Outcome
  • Myocardial Infarction
  • Middle Aged
  • Matrix Metalloproteinase Inhibitors
  • Male
  • Hydroxamic Acids
  • Humans
  • Female